AVSU Fees and Costs — Avantis Responsible U.S. Equity ETF

Data updated: 2026-07-29

The net expense ratio is 0.15%. There are no sales loads or redemption fees. In fiscal 2024 the fund paid $3K in broker commissions, 0.0013% of average net assets, and portfolio turnover was 1%.

AVSU Fees and Expenses

Annual operating expenses and sales charges of AVSU. Prospectus, as of January 1, 2026.

Annual operating expenses
Management fee0.15%
12b-1 fee—
Other expenses0.00%
Gross expense ratio0.15%
Fee waiver—
Net expense ratio0.15%
Sales charges
Max front load—
Max deferred load—
Redemption fee—
Expense limitation in place (N-CEN)No
Fees waived or reduced during the yearNo
Waived fees subject to recoupmentNo

AVSU Costs Over Time

On $10,000 invested in AVSU, assuming 5% a year before costs, total costs come to $96 over 5 years, cutting the return by 0.16% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).

$10,000 investedSell after 1 yearSell after 3 yearsSell after 5 years
Value before costs$10,500$11,576$12,763
Fund expenses (net expense ratio 0.15%)$16$50$87
Trading costs (broker commissions)$0$0$1
Lost growth on money paid in costs$0$2$9
Total costs$16$52$96
Value after costs$10,484$11,524$12,667
Impact on return, per year0.16%0.16%0.16%

AVSU Trading Costs

Brokerage costs reported on SEC Form N-CEN for the fiscal year ending August 31, 2024.

  • Explicit cost rate (commissions ÷ average net assets): 0.0013%
  • Total broker commissions: $3K
  • Bought from dealers (principal trades, not a cost): $120K
  • Portfolio turnover (prospectus): 1%
  • Securities on loan, average value: $262K
  • Net income from securities lending: $7K (0.003% of average net assets)

AVSU Agency Brokers

Commissions paid.

BrokerAmountShare
Jefferies LLC$95731.67%
Goldman Sachs$74124.52%
Bank of America Merrill Lynch$56018.53%
Sanford C. Bernstein$41813.81%
J.P. Morgan Securities$34711.47%

AVSU Dealer Counterparties

Securities bought directly from dealers (principal trades).

BrokerAmountShare
Monster Beverage Corp$105K87.56%
Deciphera Pharmaceuticals In$15K12.44%

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.